B. Metzler seel. Sohn & Co. AG Buys 6,407 Shares of Johnson & Johnson $JNJ

B. Metzler seel. Sohn & Co. AG boosted its stake in Johnson & Johnson (NYSE:JNJ) by 1.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 442,855 shares of the company’s stock after acquiring an additional 6,407 shares during the quarter. Johnson & Johnson accounts for 0.8% of B. Metzler seel. Sohn & Co. AG’s portfolio, making the stock its 27th largest position. B. Metzler seel. Sohn & Co. AG’s holdings in Johnson & Johnson were worth $73,443,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. Brighton Jones LLC increased its stake in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the last quarter. Hudson Value Partners LLC grew its position in shares of Johnson & Johnson by 2.5% in the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock valued at $5,648,000 after acquiring an additional 1,022 shares during the period. Bellwether Advisors LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $97,000. Perbak Capital Partners LLP bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $1,554,000. Finally, AQR Capital Management LLC grew its position in shares of Johnson & Johnson by 9.9% in the 4th quarter. AQR Capital Management LLC now owns 3,472,635 shares of the company’s stock valued at $500,094,000 after acquiring an additional 313,672 shares during the period. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Bank of America lifted their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Thursday, July 17th. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Leerink Partnrs downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Guggenheim reaffirmed a “neutral” rating and set a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $176.29.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $176.63 on Wednesday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The firm has a market cap of $425.39 billion, a price-to-earnings ratio of 18.89, a P/E/G ratio of 2.27 and a beta of 0.41. The firm’s 50-day simple moving average is $164.44 and its 200 day simple moving average is $159.60. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.